Luther King Capital Management (LKCM)’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $293K | Sell |
5,580
-4,863
| -47% | -$257K | ﹤0.01% | 554 |
|
|
2026
Q1 | $576K | Sell |
10,443
-10,533
| -50% | -$571K | ﹤0.01% | 464 |
|
|
2025
Q4 | $1.03M | Buy |
+20,976
| New | +$978K | ﹤0.01% | 411 |
|
|
2022
Q3 | – | Sell |
-3,880
| Closed | -$211K | – | 595 |
|
|
2022
Q2 | $211K | Buy |
+3,880
| New | +$214K | ﹤0.01% | 586 |
|
|
2022
Q1 | – | Sell |
-3,647
| Closed | -$201K | – | 620 |
|
|
2021
Q4 | $201K | Buy |
+3,647
| New | +$190K | ﹤0.01% | 604 |
|
|
2020
Q4 | – | Sell |
-4,366
| Closed | -$205K | – | 561 |
|
|
2020
Q3 | $205K | Sell |
4,366
-205
| -4% | -$10.3K | ﹤0.01% | 503 |
|
|
2020
Q2 | $233K | Sell |
4,571
-799
| -15% | -$41K | ﹤0.01% | 477 |
|
|
2020
Q1 | $254K | Sell |
5,370
-2,248
| -30% | -$120K | ﹤0.01% | 460 |
|
|
2019
Q4 | $447K | Buy |
7,618
+3,572
| +88% | +$199K | ﹤0.01% | 442 |
|
|
2019
Q3 | $216K | Sell |
4,046
-168
| -4% | -$8.64K | ﹤0.01% | 514 |
|
|
2019
Q2 | $211K | Hold |
4,214
| – | – | ﹤0.01% | 503 |
|
|
2019
Q1 | $220K | Buy |
+4,214
| New | +$211K | ﹤0.01% | 491 |
|
|
2017
Q3 | – | Sell |
-4,346
| Closed | -$234K | – | 509 |
|
|
2017
Q2 | $234K | Buy |
4,346
+44
| +1% | +$2.35K | ﹤0.01% | 464 |
|
|
2017
Q1 | $227K | Sell |
4,302
-1,237
| -22% | -$62.8K | ﹤0.01% | 483 |
|
|
2016
Q4 | $267K | Buy |
5,539
+1,102
| +25% | +$54.4K | ﹤0.01% | 462 |
|
|
2016
Q3 | $239K | Sell |
4,437
-141
| -3% | -$7.73K | ﹤0.01% | 467 |
|
|
2016
Q2 | $248K | Sell |
4,578
-659
| -13% | -$34.7K | ﹤0.01% | 470 |
|
|
2016
Q1 | $265K | Buy |
5,237
+280
| +6% | +$13.9K | ﹤0.01% | 463 |
|
|
2015
Q4 | $250K | Sell |
4,957
-407
| -8% | -$20.7K | ﹤0.01% | 483 |
|
|
2015
Q3 | $258K | Sell |
5,364
-753
| -12% | -$39.2K | ﹤0.01% | 476 |
|
|
2015
Q2 | $318K | Buy |
6,117
+517
| +9% | +$29.1K | ﹤0.01% | 480 |
|
|
2015
Q1 | $323K | Sell |
5,600
-1,616
| -22% | -$92.6K | ﹤0.01% | 476 |
|
|
2014
Q4 | $386K | Hold |
7,216
| – | – | ﹤0.01% | 463 |
|
|
2014
Q3 | $415K | Sell |
7,216
-160
| -2% | -$9.81K | ﹤0.01% | 469 |
|
|
2014
Q2 | $493K | Buy |
7,376
+3,046
| +70% | +$206K | ﹤0.01% | 452 |
|
|
2014
Q1 | $289K | Sell |
4,330
-879
| -17% | -$59.4K | ﹤0.01% | 480 |
|
|
2013
Q4 | $348K | Sell |
5,209
-29,430
| -85% | -$1.91M | ﹤0.01% | 466 |
|
|
2013
Q3 | $2.17M | Buy |
34,639
+2,119
| +7% | +$136K | 0.02% | 334 |
|
|
2013
Q2 | $2.03M | Buy |
+32,520
| New | +$2.06M | 0.02% | 333 |
|
Other funds holding GSK
JEST
Luther King Capital Management (LKCM)'s GSK Position: Q2 2026 in Review
Luther King Capital Management (LKCM) reduced its GSK (GSK) stake by 47% in Q2 2026, selling an estimated $257K and leaving 5,580 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #554.
Luther King Capital Management (LKCM) first reported a position in GSK in Q2 2013 and has held it in 29 quarters since. The position peaked at $2.17M in Q3 2013. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Luther King Capital Management (LKCM) held 5,580 shares of GSK worth $293K as of Q2 2026.
- Luther King Capital Management (LKCM) sold 4,863 GSK shares in Q2 2026, an estimated $257K.
- GSK made up ﹤0.01% of Luther King Capital Management (LKCM)'s portfolio in Q2 2026, its #554 holding.
- Luther King Capital Management (LKCM) first reported a position in GSK in Q2 2013 and has held it in 29 quarters since.
- Luther King Capital Management (LKCM)'s GSK position peaked at $2.17M in Q3 2013.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2026, filed 10 Aug 2026.